Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Patient-Derived Xenografts of Upper Tract Urothelial Cell Carcinoma: a tool for precision medicine

ABSTRACT: Patient-Derived Xenografts of Upper Tract Urothelial Cell Carcinoma: a tool for precision medicine

PROVIDER: PRJNA554654 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9685080_1.fastq.gz	Fastqsanger.gz
	SRR9685080_2.fastq.gz	Fastqsanger.gz
	SRR9685090_1.fastq.gz	Fastqsanger.gz
	SRR9685090_2.fastq.gz	Fastqsanger.gz
	SRR9685100_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 184

Similar Datasets

Patient-Derived Xenografts of Upper Tract Urothelial Cell Carcinoma: a tool for precision medicine

Project description:Treatment paradigms for patients with upper tract urothelial carcinoma (UTUC) are typically extrapolated from studies of bladder cancer despite their distinct clinical and molecular characteristics. A major hurdle to the advancement of UTUC research is the lack of disease-specific models. Here, we report the establishment of patient derived xenograft (PDX) and cell lines models that reflect the heterogeneity of the human disease. Models demonstrated high genomic concordance with the tumors from which they were derived with muscle-invasive tumors more likely to successfully engraft. Treatment of PDX with chemotherapy recapitulated responses observed in the patients. Analysis of a S310F HER2 mutant PDX suggested that an antibody drug conjugate targeting HER2 would have superior efficacy to HER2-selective kinase inhibitors. In sum, the biologic and phenotypic concordance between patient and PDXs suggests that these models could facilitate studies of intrinsic and acquired resistance and the development of personalized medicine strategies for UTUC patients.

2020-01-29 | GSE134292 | GEO

PDX bank from urothelial cancer to guide precision medicine.

Project description:PDX bank from urothelial cancer to guide precision medicine.

| PRJNA754098 | ENA

“Direct to Drug” screening as a precision medicine tool in multiple myeloma

Project description:“Direct to Drug” screening as a precision medicine tool in multiple myeloma

| PRJNA627346 | ENA

Precision Medicine for Inherited Retinal Degenerations

Project description:Precision Medicine for Inherited Retinal Degenerations

| PRJNA736120 | ENA

Precision Medicine for Inherited Retinal Degenerations

Project description:Precision Medicine for Inherited Retinal Degenerations

| PRJNA736121 | ENA

The Brazilian Initiative on Precision Medicine (BIPMed)

Project description:The development of precision medicine strategies requires prior knowledge of the genetic background of the target population. However, despite the availability of data from admixed Americans within large reference population databases, we cannot use these data as a surrogate for that of the Brazilian population. This lack of transferability is mainly due to differences between ancestry proportions of Brazilian and other admixed American populations. To address the issue, a coalition of research centres created the Brazilian Initiative on Precision Medicine (BIPMed), an initiative of five Research Innovation and Dissemination Centers (RIDCs) supported by FAPESP.

2020-08-22 | GSE156652 | GEO

The Brazilian Initiative on Precision Medicine (BIPMed)

Project description:The Brazilian Initiative on Precision Medicine (BIPMed)

| PRJNA658602 | ENA

Precision medicine for ABCA4 disease: modifier alleles

Project description:Precision medicine for ABCA4 disease: modifier alleles

| PRJNA717338 | ENA

Precision medicine for ABCA4 disease: modifier alleles

Project description:Precision medicine for ABCA4 disease: modifier alleles

| PRJNA717339 | ENA

PDX bank from urothelial cancer to guide precision medicine.

Project description:We developed preclinical PDX models, recapitulating the molecular heterogeneity of MIBCs and UTUC, which will represent an essential tool in therapy development. Pharmacological characterization of the PDXs suggested that upper urinary tract and bladder cancers (UCC/ SCC) with similar molecular characteristics could benefit from the same treatments, and showed a benefit for combined FGFR/EGFR inhibition in FGFR3-mutant PDXs, compared to FGFR inhibition alone.

2022-08-31 | GSE181962 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data